Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

Related-Party Transactions - Related Party Expenses (Detail)

Related-Party Transactions - Related Party Expenses (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Research	$ 1,524,631us-gaap_ResearchAndDevelopmentExpense	$ 1,222,745us-gaap_ResearchAndDevelopmentExpense	$ 5,600,421us-gaap_ResearchAndDevelopmentExpense	$ 9,411,856us-gaap_ResearchAndDevelopmentExpense
TUM [Member]
Related Party Transaction [Line Items]
Transfer of licenses and protective rights	14,057	17,131	66,461	66,390
Research				22,573
Total expenses	$ 14,057	$ 17,131	$ 66,461	$ 88,963

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References + Details